Kowal Investment Group’s Travere Therapeutics TVTX Stock Holding History

Kowal Investment Group’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-20	Closed	–	–	875
2021 Q3	$0	Buy	+20	New	+$367	﹤0.01%	1017

Other funds holding TVTX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Kowal Investment Group's TVTX Position: Q4 2021 in Review

Kowal Investment Group sold out of Travere Therapeutics (TVTX) in Q4 2021, closing a stake of 20 shares.

Kowal Investment Group first reported a position in TVTX in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 169 funds tracked by Wall St. Rank hold TVTX as of Q4 2021.

Kowal Investment Group reported no remaining Travere Therapeutics position as of Q4 2021 after selling out during the quarter.
Kowal Investment Group sold 20 Travere Therapeutics shares in Q4 2021.
Kowal Investment Group first reported a position in Travere Therapeutics in Q3 2021 and held it in 1 quarter.
Kowal Investment Group's Travere Therapeutics position peaked at $0 in Q3 2021.
169 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2021.

Based on Kowal Investment Group's 13F filing for Q4 2021, filed 11 Feb 2022.